ATE195553T1 - Kristallisierung von m-csf - Google Patents

Kristallisierung von m-csf

Info

Publication number
ATE195553T1
ATE195553T1 AT93915279T AT93915279T ATE195553T1 AT E195553 T1 ATE195553 T1 AT E195553T1 AT 93915279 T AT93915279 T AT 93915279T AT 93915279 T AT93915279 T AT 93915279T AT E195553 T1 ATE195553 T1 AT E195553T1
Authority
AT
Austria
Prior art keywords
csf
antagonists
directed
agonists
crystallization
Prior art date
Application number
AT93915279T
Other languages
English (en)
Inventor
Jayvardhan Pandit
Jarmila Jancarik
Sung-Hou Kim
Kirston Koths
Robert Halenbeck
Anna Lisa Fear
Eric Taylor
Ralph Yamamoto
Andrew Bohm
Original Assignee
Chiron Corp
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp, Univ California filed Critical Chiron Corp
Application granted granted Critical
Publication of ATE195553T1 publication Critical patent/ATE195553T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7153—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for colony-stimulating factors [CSF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT93915279T 1992-06-09 1993-06-09 Kristallisierung von m-csf ATE195553T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89651292A 1992-06-09 1992-06-09
PCT/US1993/005548 WO1993025687A1 (en) 1992-06-09 1993-06-09 Crystallization of m-csf

Publications (1)

Publication Number Publication Date
ATE195553T1 true ATE195553T1 (de) 2000-09-15

Family

ID=25406334

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93915279T ATE195553T1 (de) 1992-06-09 1993-06-09 Kristallisierung von m-csf

Country Status (7)

Country Link
US (2) US5866114A (de)
EP (2) EP0668914B1 (de)
JP (2) JPH08507916A (de)
AT (1) ATE195553T1 (de)
CA (1) CA2137793C (de)
DE (1) DE69329247T2 (de)
WO (1) WO1993025687A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5581476A (en) * 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
US6372219B1 (en) * 1996-03-14 2002-04-16 Univ Illinois Parasite-derived anti-inflammatory immunomodulatory protein
WO2001034177A2 (en) * 1999-11-08 2001-05-17 The Government Of The United States Of America, A S Represented By The Secretary, Department Of Hea Lth & Human Services, The National Institutes Of Health Method of treating a viral infection using antagonists of macrophage colony stimulating factor
CN100439397C (zh) 2001-02-09 2008-12-03 基因技术股份有限公司 Igf-1的结晶
US7247618B2 (en) * 2001-04-30 2007-07-24 Tripathi Rajavashisth Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling
EP1425304B9 (de) 2001-07-11 2010-09-08 Maxygen, Inc. G-csf konjugate
US7563595B2 (en) * 2002-11-08 2009-07-21 University Of South Florida Nucleic acids encoding functional splice variants of the α7 nicotinic acetylcholine receptor subunit and methods for producing the encoded proteins
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
US20050124008A1 (en) * 2003-12-05 2005-06-09 Kauvar Lawrence M. Homogeneous competition assays
JP2007524671A (ja) * 2004-01-21 2007-08-30 カイロン コーポレイション Ｍ−ｃｓｆムテインおよびその使用
WO2006047505A2 (en) * 2004-10-22 2006-05-04 Janssen Pharmaceutica, N.V. Crystal structure of the c-fms kinase domain
KR20080027291A (ko) 2005-06-01 2008-03-26 맥시겐 홀딩스 엘티디 피이지화된 지-씨에스에프 폴리펩타이드 및 그 제조방법
KR100970770B1 (ko) 2008-02-12 2010-07-16 한국기초과학지원연구원 결정성 재조합 단백질 휴먼 에스피오티 및 이의 결정화방법
US8183207B2 (en) * 2008-11-26 2012-05-22 Five Prime Therapeutics, Inc. Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules
WO2010062399A2 (en) * 2008-11-26 2010-06-03 Five Prime Therapeutics, Inc. Csf1r extracellular domain fusion molecules and treatments using same
TWI504598B (zh) * 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
ES2722300T3 (es) 2009-12-10 2019-08-09 Hoffmann La Roche Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso
US9169323B2 (en) 2010-03-05 2015-10-27 Hoffmann-La Roche Inc. Antibodies against human CSF-1R
JP5989547B2 (ja) 2010-03-05 2016-09-07 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ヒトｃｓｆ−１ｒに対する抗体及びその使用
HRP20190047T1 (hr) 2010-05-04 2019-02-22 Five Prime Therapeutics, Inc. Protutijela koja se vežu na csf1r
WO2013036829A1 (en) 2011-09-09 2013-03-14 Genentech, Inc Treatment of th17 mediated inflammatory diseases
RU2658603C2 (ru) 2011-12-15 2018-06-21 Ф.Хоффманн-Ля Рош Аг Антитела против человеческого csf-1r и их применения
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
SG11201610672YA (en) 2014-06-23 2017-01-27 Five Prime Therapeutics Inc Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
EP3212670B1 (de) 2014-10-29 2020-12-23 Five Prime Therapeutics, Inc. Kombinationstherapie gegen krebs
MX2017008218A (es) 2014-12-22 2017-10-18 Five Prime Therapeutics Inc Anticuerpos anti-csf1r para tratar pvns.
AU2016249981B2 (en) 2015-04-13 2022-02-17 Five Prime Therapeutics, Inc. Combination therapy for cancer
CN109790220A (zh) 2016-08-25 2019-05-21 豪夫迈·罗氏有限公司 与巨噬细胞激活剂组合的抗csf-1r抗体的间歇给药
CN110072553B (zh) 2016-12-22 2023-09-15 豪夫迈·罗氏有限公司 在抗pd-l1/pd1治疗失败之后抗csf-1r抗体与抗pd-l1抗体组合对肿瘤的治疗
CN106843149A (zh) * 2017-03-28 2017-06-13 吴小江 一种机械零固件产品加工系统
EP3681535A1 (de) 2017-09-13 2020-07-22 Five Prime Therapeutics, Inc. Kombination von anti-csf1r und anti-pd-1-antikörperkombinationstherapie beibauchspeicheldrüsenkrebs

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4672108A (en) * 1981-12-07 1987-06-09 Hoffmann-La Roche Inc. Crystalline human leukocyte interferon
US4582788A (en) 1982-01-22 1986-04-15 Cetus Corporation HLA typing method and cDNA probes used therein
US4966911A (en) * 1984-11-20 1990-10-30 Washington Research Foundation Immunoregulatory agents
US4847201A (en) * 1985-02-05 1989-07-11 Cetus Corporation DNA encoding for CSF-1 and accompanying recombinant systems
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
JPS62106000A (ja) * 1985-10-30 1987-05-16 Fujitsu Ltd 生体高分子結晶自動作製装置
US4908773A (en) * 1987-04-06 1990-03-13 Genex Corporation Computer designed stabilized proteins and method for producing same
US4881175A (en) * 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5032676A (en) 1986-10-14 1991-07-16 Immunex Corporation Nonglycosylated analogs of human colony stimulating factors
WO1988003173A2 (en) * 1986-10-24 1988-05-05 Cetus Corporation New forms of colony stimulating factor-1
US4929700A (en) * 1987-04-16 1990-05-29 Cetus Corporation Production of purified, biologically active, bacterially produced recombinant human CSF-1
IL86090A (en) * 1987-04-16 1993-03-15 Cetus Oncology Corp Production of purified, biologically active, bacterially produced recombinant human csf-1
US4833233A (en) * 1987-08-20 1989-05-23 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Human serum albumin crystals and method of preparation
EP0344796B1 (de) * 1988-06-03 1994-09-21 Chugai Seiyaku Kabushiki Kaisha Menschlicher kristallinischer Granulocyt-Koloniestimulierungsfaktor und dessen Herstellung
US5109119A (en) * 1989-06-06 1992-04-28 Schering Corporation Crystalline r-h-gm-csf and method
IE66494B1 (en) * 1989-09-26 1996-01-10 Immunex Corp Granulocyte-colony stimulating factor receptors
DE69004101T2 (de) * 1989-12-21 1994-03-24 Novonordisk As Verfahren zur kristallisation von enzymen.
JP3417558B2 (ja) * 1991-05-10 2003-06-16 ジェネンテク，インコーポレイテッド 配位子作用薬および拮抗薬の選択

Also Published As

Publication number Publication date
DE69329247D1 (de) 2000-09-21
DE69329247T2 (de) 2001-05-31
JPH08507916A (ja) 1996-08-27
EP0955365A3 (de) 2000-12-20
CA2137793C (en) 2003-04-22
EP0955365A2 (de) 1999-11-10
CA2137793A1 (en) 1993-12-23
US6184354B1 (en) 2001-02-06
WO1993025687A1 (en) 1993-12-23
EP0668914B1 (de) 2000-08-16
JP2004285076A (ja) 2004-10-14
EP0668914A1 (de) 1995-08-30
US5866114A (en) 1999-02-02

Similar Documents

Publication Publication Date Title
ATE195553T1 (de) Kristallisierung von m-csf
PT86648A (pt) Method for the preparation of anti-retroviral compositions containing 3'-azido-2',3'-dideoxyuridine
FI870113A7 (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten 4,5,6-substioitujenN-(substituoitu-fenyyli)-2-pyrimidiiniamiinien valmistamiseksi
UA39168C2 (uk) Фторалкоксифенільні похідні піперидину або хінуклідину, що є антагоністами речовини p і фармацевтична композиція на їх основі
IT8122675A0 (it) Mercaptoacil derivati di varie proline 4 sostituite e relative composizioni utili per il trattamento dell'ipertensione.
IT1222394B (it) Processo per la preparazione di 2,2,6,6 tetrametil 4 piperidilammine
ATE71627T1 (de) Bryostatine.
ATE243694T1 (de) 4-mercaptoacetylamino-(2)benzazepinon(3)- derivate, und verwendung als enkephalinase- inhibitoren
HU913792D0 (en) Method for producing serotonine antagonists
PT97478A (pt) Processo de producao de derivados n-(3-fluoro-2-fosfonilmetoxipropilo) de bases puricas e pirimidicas heterociclicas e de composicoes farmaceuticas que os contem
IT8848653A0 (it) Procedimento per il recupero di componenti di gas di sintesi privi di idrogeno
IT1217328B (it) Processo per la metallizzazione di materiali fibrosi
ES2067541T3 (es) Mejoras en antagonistas de la serotonina y relacionadas con ellos.
ES2088460T3 (es) Hexahidrobenz(cd)indoles.
FI872930A7 (fi) Analogiamenetelmä ripulinvastaisten 4-(bentsoyyliamino)piperidiinibutaaniamidijohdannaisten valmistamiseksi
ATE63543T1 (de) 2-oxindolzwischenprodukte.
TR199901395T2 (xx) Yeni karboksi ikameli siklik karboksamid t�revleri.
ES533939A0 (es) Un procedimiento de preparacion de nuevos derivados de 4-aminopiperidina
DE3876193D1 (de) Aminomethylderivate von mono- und dithiocarbamaten als schmiermitteladditive.
PT90719A (pt) Processo de preparacao de 2-etenil-3,4,5,6-tetra-hidrotieno{4,3,2-ef}{3} benzazepinas substituidas e de composicoes farmaceuticas que as contem
DE59007354D1 (de) Monohydrochlorid und Monomethansulfonat von Amonafide.
NO891681L (no) Fremgangsmaate for syntese av c5+ hydrokarboner.
ATE114310T1 (de) Alpha-adrenergische rezeptorantagonisten.
DE68903028D1 (de) Verfahren zur chemisch-biologischen entschwefelung von kohle.
IT8719647A0 (it) Processo per la sintesi dell'epsiloncaprolattame.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties